Duopharma Biotech Berhad Income Statement

Financials in millions MYR. Fiscal year is January - December.

Millions MYR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	900.68	813.7	704.73	696.72	639.18	569.9
Revenue Growth (YoY)	14.37%	15.46%	1.15%	9.00%	12.16%	-1.14%
Cost of Revenue	558.05	512.16	436.4	416.9	385.19	336.7
Gross Profit	342.62	301.54	268.33	279.82	253.98	233.2
Selling, General & Admin	217.4	202.02	182.72	186.59	165.78	150.81
Other Operating Expenses	0.58	0.7	2.8	0.81	-0.67	1.35
Operating Expenses	216.54	201.28	189.61	186.91	165.22	151.35
Operating Income	126.08	100.26	78.71	92.91	88.77	81.86
Interest Expense	-23.99	-25.77	-17.68	-9.1	-6.44	-6.53
Interest & Investment Income	5.78	5.97	2.75	1.52	1.2	1.51
Other Non Operating Income (Expenses)	-0.82	-0.82	-0.52	-0.48	-0.53	-0.68
EBT Excluding Unusual Items	107.05	79.63	63.27	84.85	82.99	76.16
Gain (Loss) on Sale of Assets	0.39	0.39	-	-	-0.01	-
Pretax Income	107.45	80.02	63.27	84.85	82.98	76.16
Income Tax Expense	23.95	17.38	10.62	14.74	17.3	17.55
Net Income	83.5	62.65	52.65	70.11	65.68	58.61
Net Income to Common	83.5	62.65	52.65	70.11	65.68	58.61
Net Income Growth	48.93%	19.00%	-24.91%	6.74%	12.07%	6.04%
Shares Outstanding (Basic)	961	962	959	948	928	928
Shares Outstanding (Diluted)	961	962	959	948	928	928
Shares Change (YoY)	-0.12%	0.36%	1.08%	2.15%	0.02%	3.86%
EPS (Basic)	0.09	0.07	0.05	0.07	0.07	0.06
EPS (Diluted)	0.09	0.07	0.05	0.07	0.07	0.06
EPS Growth	49.07%	18.57%	-25.71%	4.50%	12.05%	2.09%
Free Cash Flow	80.13	59.77	15.86	5.08	-66.16	15.24
Free Cash Flow Per Share	0.08	0.06	0.02	0.01	-0.07	0.02
Dividend Per Share	0.035	0.030	0.023	0.023	0.022	0.049
Dividend Growth	25.00%	30.44%	-	5.75%	-55.43%	8.44%
Gross Margin	38.04%	37.06%	38.07%	40.16%	39.74%	40.92%
Operating Margin	14.00%	12.32%	11.17%	13.33%	13.89%	14.36%
Profit Margin	9.27%	7.70%	7.47%	10.06%	10.28%	10.28%
Free Cash Flow Margin	8.90%	7.35%	2.25%	0.73%	-10.35%	2.67%
EBITDA	163.24	137.34	114.04	122.86	114.94	105.93
EBITDA Margin	18.12%	16.88%	16.18%	17.63%	17.98%	18.59%
D&A For EBITDA	37.16	37.08	35.32	29.95	26.18	24.08
EBIT	126.08	100.26	78.71	92.91	88.77	81.86
EBIT Margin	14.00%	12.32%	11.17%	13.33%	13.89%	14.36%
Effective Tax Rate	22.29%	21.72%	16.79%	17.37%	20.85%	23.04%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.